BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23038738)

  • 1. Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.
    Karaplis AC; Bai X; Falet JP; Macica CM
    Endocrinology; 2012 Dec; 153(12):5906-17. PubMed ID: 23038738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenic role of Fgf23 in Dmp1-null mice.
    Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice.
    Liang G; Katz LD; Insogna KL; Carpenter TO; Macica CM
    Calcif Tissue Int; 2009 Sep; 85(3):235-46. PubMed ID: 19609735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
    Rowe PS
    Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
    Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
    Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
    Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.
    Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD
    FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets.
    Ruppe MD; Brosnan PG; Au KS; Tran PX; Dominguez BW; Northrup H
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):312-8. PubMed ID: 21050253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation.
    Farrow EG; Summers LJ; Schiavi SC; McCormick JA; Ellison DH; White KE
    J Endocrinol; 2010 Oct; 207(1):67-75. PubMed ID: 20675303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPR4-peptide alters bone metabolism of normal and HYP mice.
    Zelenchuk LV; Hedge AM; Rowe PS
    Bone; 2015 Mar; 72():23-33. PubMed ID: 25460577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
    Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
    J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The wrickkened pathways of FGF23, MEPE and PHEX.
    Rowe PS
    Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1).
    Bai X; Levental M; Karaplis AC
    J Clin Endocrinol Metab; 2022 Sep; 107(10):2777-2783. PubMed ID: 35896139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice.
    Ichikawa S; Gerard-O'Riley RL; Acton D; McQueen AK; Strobel IE; Witcher PC; Feng JQ; Econs MJ
    Endocrinology; 2017 Mar; 158(3):470-476. PubMed ID: 28005411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6.
    Uchihashi K; Nakatani T; Goetz R; Mohammadi M; He X; Razzaque MS
    Contrib Nephrol; 2013; 180():124-37. PubMed ID: 23652555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypophosphatemic osteosclerosis, hyperostosis, and enthesopathy associated with novel homozygous mutations of DMP1 encoding dentin matrix protein 1 and SPP1 encoding osteopontin: The first digenic SIBLING protein osteopathy?
    Whyte MP; Amalnath SD; McAlister WH; McKee MD; Veis DJ; Huskey M; Duan S; Bijanki VN; Alur S; Mumm S
    Bone; 2020 Mar; 132():115190. PubMed ID: 31843680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
    Quarles LD
    Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
    Ichikawa S; Austin AM; Gray AK; Econs MJ
    J Bone Miner Res; 2012 Feb; 27(2):453-60. PubMed ID: 22006791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.
    Gattineni J; Baum M
    Pediatr Nephrol; 2010 Apr; 25(4):591-601. PubMed ID: 19669798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.
    David V; Martin A; Hedge AM; Drezner MK; Rowe PS
    Am J Physiol Renal Physiol; 2011 Mar; 300(3):F783-91. PubMed ID: 21177780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.